Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

Blood

Volumn 98, Issue 10, 2001, Pages 3082-3086

  Avet Loiseau, Hervé ^a,b,c   Gerson, Fabienne ^a,b   Magrangeas, Florence ^a,b   Minvielle, Stéphane ^a,b   Harousseau, Jean Luc ^a,b   Bataille, Régis ^a,b,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; MYC PROTEIN;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHROMOSOME 13; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE IDENTIFICATION; GENE ISOLATION; GENE PROBE; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN CELL; INTERPHASE; KARYOTYPING; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; ONCOGENE MYC; PLASMA CELL; PLASMA CELL DYSCRASIA; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PRIORITY JOURNAL;

EID: 0035892119     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.3082     Document Type: Article

References (32)

1. Gado K, Silva S, Paloczi K, Domian G, Falus A. Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica. 2001;86:227-236.
2. Potter M, Wiener F. Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis. 1992;13:1681-1697.
3. Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in the interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1992;89:232-235.
4. Rosenbaum H, Harris AW, Bath ML, et al. An Eμ-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J. 1990;9:897-905.
5. Marin MC, Hsu B, Stephens LC, Brisbay S, McDonnell TJ. The functional basis of c-myc and bcl2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res. 1995;217:240-247.
6. Radl J, Punt YA, van den Enden-Vieveen MH, et al. The 5T mouse multiple myeloma model: absence of c-myconcogene rearrangement in early transplant generations. Br J Cancer. 1990;61:276-278.
7. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 1988;71:453-456.
8. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41-49.
9. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960-969.
10. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A. 2000;97:228-233.
11. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998;58:5640-5645.
12. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654-3663.
13. Pegoraro L, Malavasi F, Bellone G, et al. The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood. 1989;73:1020-1027.
14. Eton O, Scheinberg DA, Houghton AN. Establishment and characterization of two human myeloma cell lines secreting K light chains. Leukemia. 1989;3:729-735.
15. Katagiri S, Yonezawa T, Kuyama J, et al. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer. 1985;36:241-246.
16. Jackson N, Lowe J, Ball J, et al. Two new IgA1-κ plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin Exp Immunol. 1989;90:93-99.
17. Nacheva E, Fischer PE, Sherrington PD, et al. A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14. Br J Haematol. 1990;74:70-76.
18. Matsuoka Y, Moore GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a haematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med. 1967;125:1246-1250.
19. Kirchner HH, Fonatsch C, Schaadt M, Günzel M, Hellriegel KP, Diehl V. Correlation of chromosomal aberrations in a myeloma cell line with tumorigenicity in nude mice. Blut. 1981;43:93-97.
20. Nilsson K, Bennich H, Johansson SG, Ponten J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol. 1970;7:477-489.
21. Shimizu S, Takiguchi T, Fukutoku M, et al. Establishment of a CD4-positive plasmacytoma cell line (AMO1). Leukemia. 1993;7:274-280.
22. Hamilton MS, Ball J, Bromidge E, Lowe J, Franklin IM. Characterization of a new IgGλ myeloma plasma cell line (EJM): a further tool in the investigation of the biology of multiple myeloma. Br J Haematol. 1990;75:378-384.
23. Jelinek DF, Ahmann GJ, Greipp PR, et al. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 1993;53:5320-5327.
24. Rack KA, Delabesse E, Radford-Weiss I, et al. Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1998;23:220-226.
25. Janssen JWG, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13; q32). Blood. 2000;95:2691-2698.
26. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457-4463.
27. Krummel KA, Roberts LR, Kawakami M, Glover TW, Smith DI. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics. 2000;69:37-46.
28. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: study of 40 cases at diagnosis. Blood. 2001;97:822-825.
29. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001;112:167-174.
30. Königsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-812.
31. Desikan R, Barlogie B, Sawyer JR, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
32. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a very powerful myeloma staging system for patients receiving high dose therapy. Blood. 2001;97:1566-1571.